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Background: Vascular endothelial growth factor (VEGF) is considered to be the most important
angiogenic factor in asthma. Cysteinyl leukotrienes (Cyst-LTs) have been implicated in vascular
permeability in asthma. Cyst-LTs receptor antagonists modulate vascular permeability by
reducing VEGF expression.
Objective: We aimed to determine the levels of VEGF and Cyst-LTs in sputum supernatants of
patients with asthma and to investigate possible associations within them and with airway
vascular permeability (AVP) index. Possible confounding factors were also assessed.
Methods: One hundred twenty one patients with asthma (38 with severe refractory asthma, 41
smokers) and 30 healthy subjects (15 smokers) were studied. All subjects underwent lung func-
tion tests, and sputum induction for cell count identification and VEGF, Cyst-LTs, measurement
in supernatants. AVP index was also assessed.
Results: Both VEGF & Cyst-LTs (pg/ml) levels were significantly elevated in patients with
asthma compared to normal subjects (median, interquartile ranges 845 [487e1034] vs. 432
(327e654) and 209 [171e296] vs. 92 [75e114] respectively, p < 0.001 for both). Multivariate
regression analysis in the whole group showed a significant association of Cyst-LTs levels in
sputum supernatants with VEGF levels in sputum supernatants and AVP index. A similar positive44380549; fax: þ30 210770423.
kides).
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1340 G. Papadaki et al.association was observed between VEGF levels in sputum supernatants and AVP index. The
presence of Severe asthma was a significant covariate for both associations.
Conclusion: Our results indicate that Cyst-LTs may modulate vascular permeability by
up-regulating VEGF expression. The above effect seems to be affected by asthma severity.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Angiogenesis is a complex multiphase process, potentially
involving a great number of growth factors, cytokines,
chemokines and numerous other mediators but the specific
role of each molecule has not been clearly defined. During
chronic inflammation, the vascular remodeling process is
the consequence of a pro-angiogenetic action, in which
many growth factors and inflammatory mediators are
involved [1]. Airway remodeling in asthma also involves an
increase in angiogenesis, a process most likely to be
mediated by several angiogenic mediators including
vascular endothelial growth factor (VEGF) [2].
VEGF is considered to be themost important angiogenetic
factor, that induces vascular endothelial cell proliferation,
tubule formation and increases microvascular permeability
[3]. The latter is a common feature of vascular remodeling in
asthma and is modulated by the release of different inflam-
matory mediators, cytokines, proteases and growth factors.
Cysteinyl leukotrienes (Cyst-LTs) are important molecules
that promote both airway inflammation and remodeling [4].
Evidence suggests that Cyst-LTs play an important role in the
airway remodeling observed in persistent asthma that in-
cludes increases of airway goblet cells, mucus, blood vessels,
smooth muscle, myofibroblasts, and airway fibrosis. Cyst-LTs
can transcriptionally activate VEGF production via cysLT1
receptors, indicating that Cyst-LTs may be important in the
angiogenic process of airway remodeling [5]. Furthermore
in vitro and in vivo studies support that the administration of a
Cyst-LTs antagonist leads to alterations of VEGF levels [6,7].
In the present study, we aimed to determine the levels
of both Cyst-LTs and VEGF in sputum supernatants of pa-
tients with asthma and to investigate possible associations
with airway vascular permeability as assessed by airway
vascular permeability (AVP) index. Furthermore, we wan-
ted to determine whether significant confounding factors
such as underlying severity, atopy and smoking significantly
affect the above mediators and processes.
Materials & methods
Subjects
Patients were recruited from an open cohort of asthmatic
patients who were followed up in the asthma clinics of the
1st and 2nd Respiratory Medicine University Departments in
Athens for at least 2 years. The recruitment period was
between June 2008 and September 2012. The diagnosis of
asthma was established according to GINA guidelines [8].
The diagnosis of Severe Refractory asthma (SRA) was
established according to ATS criteria [9]. Patients
with symptoms of acute rhinitis, nasal congestion,
nasal polyps, or a history of aspirin hypersensitivity wereexcluded since these conditions are related to eicosanoid
inflammation [10e12]. Patients receiving leukotriene
modifiers were also excluded. Subjects with any other
respiratory disease or any concomitant malignant, heart,
renal, liver or collagen disease were excluded. Patients
with a respiratory tract infection or asthma exacerbation in
the past 8 weeks prior to admission were also excluded. The
study was approved by the ethics committees of both hos-
pitals and all subjects provided an informed consent.
Induced sputum
Sputum was induced as previously described using all the
modifications for safe measurements according to the
underlying asthma severity [13,14]. Briefly, patients
inhaled 3% saline at room temperature nebulized by an
ultrasonic nebulizer (DeVilbiss Co., Heston, UK) at the
maximal saline output (4 ml/min). The total period of
sputum induction was 15 min. Subjects were encouraged
to cough deeply at 3-min intervals until the 15-min in-
duction time had been completed. Sputum was processed
using selected plugs as previously described [15]. Dithio-
threitol (DTT) was added in a volume equal to four times
the weight of the sputum specimen and it was further
diluted with phosphate buffered saline (PBS) in a volume
equal to the sputum plus DTT. Total cell counts were
performed on a hemacytometer using Trypan blue stain.
Slides were prepared by using cytospin (Shandon, Run-
corn, UK) and were stained with May-Grunwald and Gi-
emsa for differential cell counts. Cell counting was
performed by an observer blind to the clinical charac-
teristics of the subjects. At least 500 inflammatory cells
were counted in each sample. A sample was considered
adequate when the patient was able to expectorate at
least 2 ml of sputum and the slides contained <10%
squamous cells on differential cell counting. Total cell
count expressed as the number of cells  106 and the
percentage (%) of sputum inflammatory cells were used
for our analysis. Sputum supernatants were kept at 70 C
for further measurement of Cyst-LTs, VEGF and albumin.
Lung function
Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC), were measured using Master Screen Body
(Viasys Healthcare, Jaeger, Hoechberg, Germany) accord-
ing to the American Thoracic Society guidelines [16].
Atopic status
A positive skin prick test to any of twenty common aero-
allergens (including mites, grasses, trees, fungus, domestic
animals) was used to confirm atopy.
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VEGF was measured using an enzyme-linked immunosor-
bent assay kit (ELISA, R&D systems, Minneapolis, Minne-
sota, USA with detection limits of 9 pg/ml). Cyst-LTs were
measured using an ELISA kit (detection limit 13 pg/ml,
Cayman Chemical, Ann Arbor MI, USA). The intra and inter
assay variability were assessed according to the manufac-
turer’s instructions for all the mediators measured and
were within acceptable Coefficient of variation (CV) %
(4% and 5.5% respectively for VEGF and Cyst-LTs). The re-
covery and linearity of the assays after appropriate spiking
experiments produced samples with values within the dy-
namic range of the assay. Blood was drawn for determina-
tion of serum albumin. The airway vascular permeability
(AVP) index was calculated as the ratio of albumin con-
centrations in induced sputum and serum [17].
Study design
On day 1, all subjects underwent medical history and
physical examination by an experienced respiratory physi-
cian, lung function measurements, BMI measurement, and
skin prick tests. The day after, blood samples were taken
and sputum induction was performed.Table 1 Subjects characteristics and inflammatory variables.
Asthma (all)
N Z 121
Age 53 [42e63]
Gender F/M 70/51
Atopy 81/121
Smokers 41/121
Pack years 50 [30e55]
Duration of asthma (years) 29 [21e42]
BMI kg/m2 27 [24e29]
FeNO ppb 19 [14e28]
FEV1% pred 82  17
FEV1/FVC 68 [64e78]
Cells  106/ml 1.7 [1e3]
Eosinophils% 4 [2e9]
Neutrophils% 35 [22e44]
Macrophages% 57  17
Lymphocytes % 1 [0e2.2]
VEGF (pg/ml) 845 [487e1034]
Cyst-LTs (pg/ml) 209 [171e296]
AVP index 0.036 [0.02e0.053]
Treatment regimens
ICS 121
LABA 97
Oral Cs 19
Omalizumab 9
Normally distributed data are presented as mean  standard deviat
quartile ranges). Abbreviations: MZ Male, FZ Female, BMIZ Body m
expiratory volume in 1 s, FVCZ Forced vital capacity, AVP: Airway va
Cyst-LTs Z Cysteinyl leukotrienes. Bold numbers indicate significant
LABAZ Long acting b2 agonists, Cs-Corticosteroids, NAZ Not applicab
across the two groups.Statistical analysis
Normally distributed data was presented as mean 
standard deviation (SD), whereas skewed data was
presented as median (interquartile ranges). Normality of
distribution was checked with KolmogoroveSmirnov
test. Statistical comparisons between groups were per-
formed with one way analysis of variance (ANOVA) for
normally distributed data and with KruskaleWallis tests
for skewed data, accompanied by appropriate post-hoc
tests for multiple comparisons (Bonferroni and Dunn’s,
respectively). Differences in numerical variables within
two groups were evaluated with unpaired t-tests or
ManneWhitney U-tests for normally and skewed data
respectively, whereas comparisons of proportions were
performed using chi-square tests. In order to examine the
association between VEGF & Cyst-LTs, inflammatory cells,
AVP index and lung function tests, multivariate linear
regression analysis was performed using VEGF & Cyst-LTs,
as the dependent variables. Linear regression analysis was
performed in one model using presence of SRA, smoking,
age, gender, BMI, atopy, history of rhinitis, duration of the
disease and treatment regimens as covariates. Data were
interpreted as standardized coefficients with 95% confi-
dence intervals. A p value <0.05 (2-sided) was considered
significant. Statistical analysis was performed using SPSSNormals P value
N Z 30
46 [39e56] 0.165
18/12 0.450
NA ND
15/30 0.315
42 [31e49] 0.126
NA ND
27.5 [23.5e28] 0.587
11 [8e16] <0.001
97  11 <0.001
94 [86e101] <0.001
0.9 [0.6e1.2] 0.030
0.5 [0e1] <0.001
27 [21e34] 0.020
67 [54e75] 0.010
0.5 [0e1] 0.689
432 (327e654) <0.001
92 [75e114] <0.001
0.012 [0.007e0.0122] <0.001
N/A
ion (SD), whereas skewed data are presented as median (inter-
ass index, FeNOZFraction of exhaled nitric oxide, FEV1Z Forced
scular permeability, VEGFZ Vascular endothelial growth factor,
differences across the two groups. ICS Z inhaled corticosteroids,
le, NDZ Not done. Bold numbers indicate significant differences
1342 G. Papadaki et al.16.0 (Chicago, Illinois, USA) and Graph Pad Prism 5 (Graph
Pad Software, California, USA).
Results
One hundred twenty one patients with asthma were
recruited. Thirty eight of them (31%) had SRA while the
remaining eighty three (69%) had mild to moderate asthma.
Among asthmatic patients, 41 (33%) were smokers. Thirty
healthy, non-atopic, subjects (15 smokers) comprised the
control group. Subjects’ demographic characteristics and
inflammatory variables are summarized in Table 1. Similar
data for the three asthma sub-groups are provided in Table
2. SRA patients were all receiving >1200 mg budesonide/
day or equivalent plus long acting beta-2 agonists (LABA),
whereas patients with mild to moderate asthma were
receiving <800 mg budesonide/day or equivalent. Among
SRA patients, 11 were also receiving 5 mg prednisolone/day
while 6 were receiving 7.5 mg prednisolone/day with the
remaining 2 receiving 10 mg prednisolone/day. Sputum in-
duction was well tolerated by all patients.
VEGF and Cyst-LTs levels [pg/ml] were significantly
higher in patients with asthma compared to normal sub-
jects (Table 1, Figs. 1 and 2). Patients with SRA had
significantly higher levels for both VEGF and Cyst-LTs
compared to milder forms of the disease, both in smokingTable 2 Subjects characteristics and inflammatory variables in
SRA M
no
N Z 38 N
Age 52 [43e59] 55
Gender F/M 24/14 25
Atopy 27/38 28
Smokers/Pack years 0 0
Duration of asthma (years) 28 [20e38] 30
BMI kg/m2 27 [25e30] 27
FEV1% pred 64  14a,b 87
FEV1/FVC 64  7a,b 73
Cells  106/ml 2.75 [1.4e3.7]a,b 1.
Eosinophils% 10 [4e16]a,b 4
Neutrophils% 40 [30e46]a 23
Macrophages% 48  15a,b 61
Lymphocytes % 1 [0e2] 1.
VEGF (pg/ml) 1055 [909e1563]a,b 56
Cyst-LTs (pg/ml) 270 [213e387]a,b 16
AVP index 0.045 [0.031e0.057]a,b 0.
Treatment regimens
ICS 38 42
LABA 38 28
Oral Cs 19 0
Omalizumab 9 0
Normally distributed data are presented as mean  standard deviat
quartile ranges). Abbreviations: M Z Male, F Z Female, BMI Z
FEV1Z Forced expiratory volume in 1 s, FVCZ Forced vital capacity,
growth factor, Cyst-LTsZ Cysteinyl leukotrienes. ICSZ Inhaled cortic
ND Z Not done. Bold numbers indicate significant differences across
a Statistically significant difference compared to mild to moderate
b Statistically significant difference compared to mild to moderateand in non-smoking subjects (Table 2, Figs. 1 and 2).
Smoking significantly increases the levels of Cyst-LTs in
patients with mild to moderate asthma (Table 2, Figs. 1 and
2). The AVP index was significantly higher in patients with
asthma compared to normal subjects and was significantly
affected by both underlying severity and smoking habit
(Table s 1 and 2, Fig. 3).
Eosinophils (%) in induced sputum were significantly
higher in patients with SRA compared to smoking and non-
smoking mild to moderate ones (Table 2). Both patients
with SRA and smoking asthmatics had significantly higher
percentages of neutrophils in sputum compared to non-
smoking ones with milder form of the disease (Table 2).
Associations
Major findings from regression analysis are summarized in
Table 3. Multivariate regression analysis in the whole group
showed a significant association of Cyst-LTs levels in sputum
supernatants with VEGF levels in sputum supernatants and
AVP index. A similar positive association was observed be-
tween VEGF levels in sputum supernatants and the AVP
index. The presence of SRA was a significant covariate for
both associations (Table 3). No other significant associa-
tions were observed. In normal subjects the aforemen-
tioned associations were not observed.asthma subgroups.
ild to moderate
n-smoking asthma
Mild to moderate
smoking asthma
P value
Z 42 N Z 41
[42e60] 47 [34e60] 0.205
/17 21/20 0.101
/42 25/41 0.632
50 [30e55] ND
[23e39] 28.5 [22e39] 0.705
[24e30] 26.5 [23e28] 0.619
 13 91  12 <0.001
 10 74  9 <0.001
2 [0.7e2.3] 1.7 [1.1e2.9] 0.005
[2e8] 2 [2e5] <0.001
[20e40]b 38 [23e44] 0.002
 17 59  15 0.010
75 [1e3] 1 [0e2.5] 0.554
7 (483e860) 673 [444e875] <0.001
9 [148e198]b 209 [181e328] <0.001
024 [0.017e0.042]b 0.036 [0.028e0.066] <0.001
41 ND
31
0
0
ion (SD), whereas skewed data are presented as median (inter-
Body mass index, FeNO Z Fraction of exhaled nitric oxide,
AVP: Airway vascular permeability, VEGFZ Vascular endothelial
osteroids, LABAZ Long acting b2 agonists, CsZ Corticosteroids,
the three groups.
non-smoking asthma.
smoking asthma.
Figure 3 AVP index [All, Severe refractory (SRA), mild to
moderate (non-smoking (NS), smoking (S)] and healthy subjects
[all, non-smoking (NS), smoking (S)], *p < 0.001 in favor of
asthma, **p < 0.001-values indicate differences across the 3
groups, p^ < 0.001 in favor of SRA, p^ < 0.001 in favor of smoking
asthma, #p Z 0.806 indicate no significant difference. Values
are presented as median interquartile ranges.
Figure 1 VEGF values [pg/ml] in patients with asthma [All,
Severe refractory (SRA), mild to moderate (non-smoking (NS),
smoking (S)] and healthy subjects [all, non-smoking (NS),
smoking (S)], *p < 0.001 in favor of asthma, **p < 0.001-values
indicate differences across the 3 groups, p^ < 0.001 in favor of
SRA, p^ < 0.001 in favor of smoking asthma, #pZ 0.709 indicate
no significant difference. Values are presented as median
interquartile ranges.
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The current study showed that both VEGF and Cyst-LTs
were up-regulated in sputum supernatant of patients with
asthma, being more increased in patients with SRA
compared to those with mild to moderate asthma.
Furthermore, they were both closely associated with the
AVP index, but these associations were mainly affected by
the presence of SRA.Figure 2 Cyst-LTs values [pg/ml] in patients with asthma
[All, Severe refractory (SRA), mild to moderate (non-smoking
(NS), smoking (S)] and healthy subjects [all, non-smoking (NS),
smoking (S)], *p < 0.001 in favor of asthma, **p < 0.001-values
indicate differences across the 3 groups, p^ < 0.001 in favor of
SRA, p^ > 0.05, #p Z 0.653 indicate no significant difference.
Values are presented as median interquartile ranges.Angiogenesis is a complicated multi-step process which
is regulated by several angiogenic factors. It is well known
that VEGF is the most potent angiogenic mediator [18]. It is
increased in the airways of patients with asthma [19e21], it
is implicated in the microvascular permeability process
and finally correlates with mucosal vascularity [19]. By
increasing vascular permeability, VEGF permits the leakage
of many mediators in the extravascular space which indi-
rectly leads to mucosal edema and airway obstruction [21].
Cyst-LTs are major eicosanoid products of activated
eosinophils, mast cells, basophils and monocytes, and have
been implicated in the pathogenesis of asthma. The
contribution of Cyst-LTs in the remodeling process seen in
asthma involves new vessel formation which is considered a
characteristic of angiogenesis seen in vascular remodeling
[4]. An in vitro study supports that Leukotriene C4 is, at
least, one of the important factors involved in angiogenesis
during inflammatory processes by stimulating tube forma-
tion and endothelial cell migration [22]. In another study,
leukotrienes C4 and D4 promoted angiogenesis in the chick
chorioallantoic membrane in vivo via a receptor-mediated
interaction [23]. In a recently published study where
human monocytes and bronchial smooth muscle cells were
purified from peripheral blood obtained from normal do-
nors, Cyst-LTs and specifically LTD4 transcriptionally acti-
vated VEGF production via Cyst-LT1 receptors, suggesting
the importance of cysLTs in the angiogenic process of
airway remodeling[5].
Mast cells are considered key cells for Cyst-LTs produc-
tion. Mast cells also enhance the migration of endothelial
cells in growing capillaries supporting a significant roles of
mast cells in angiogenesis [24]. Moreover, mast cells pro-
duce and secrete VEGF, which has been shown to stimulate
mast cell migration at sites of angiogenesis [25]. According
to the above published data, Cyst-LTs and VEGF may have a
common cellular source, the mast cell, which may partially
explain their association and contribution to angiogenesis.
Table 3 Multivariate Regression analysis (in one model-major findings) between VEGF & Cyst-LTs, inflammatory cells, AVP
index and co-variates in the whole group of patients with asthma. The values of Table 3 need to be aligned.
Variables Cyst-LTs (pg/ml) VEGF (pg/ml)
b standardized
coefficient [95% CI]
Adjusted
R2
p value b standardized
coefficient [95% CI]
Adjusted
R2
p value
Total cells 0.036 [-17,11] 0.0008 0.774 0.047 [16, 8] 0.001 0.550
Eosinophils % 0.007 [11, 11] 0.0009 0.836 0.125 [6, 2] 0.003 0.117
Neutrophils% 0.006 [5.5, 3] 0.0008 0.503 0.026 [3, 5] 0.005 0.723
Cyst-LTs [pg/ml] N/A N/A N/A 0.289 [0.36, 1] 0.299 <0.001a
AVP index 0.284 [30.161] 0.168 0.004a 0.237 [1629, 7269] 0.197 0.020a
VEGF [pg/ml] 0.289 [0.36, 1] 0.299 <0.001a N/A N/A N/A
Presence of SRA 0.564 [214, 462] 0.415 <0.001a 0.704 [449, 762] 0.635 <0.001a
Smoking 0.007 [1353, 1246] 0.005 0.736 0.160 [8, 5] 0.098 0.095
Duration of the disease 0.075 [325, 781] 0.007 0.427 0.13 [1, 4] 0.002 0.167
BMI 0.006 [281, 704] 0.006 0.324 0.17 [17, 8] 0.011 0.218
Presence of Rhinitis 0.011 [311, 801] 0.004 0.526 0.18 [67, 4] 0.810 0.090
Atopy 0.034 [342, 679] 0.007 0.308 0.04 [43, 27] 0.004 0.657
Cs per os 0.026 [27, 73] 0.002 0.170 0.035 [23, 103] 0.005 0.604
Regression analysis was performed in one model using age, gender, BMI, atopy, duration of the disease, presence of SRA, presence of
rhinitis, smoking and treatment regimens as covariates.
a Indicate significant association. Abbreviations: AVP Z Airway Vascular Permeability, VEGF Z Vascular endothelial growth factor,
Cyst Z LTs-Cysteinyl leukotrienes, SRA Z Severe refractory asthma, BMI Z Body mass index, CI Z Confidence intervals, NA Z Not
applicable.
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esis process through the enhancement of the production of
an angiogenetic factor such as VEGF. This direct linkage has
been supported in a previous experimental study at a
cellular level, where. LTD4 induced the expression of VEGF,
via the Cyst-LT1 receptor, at both the mRNA and protein
levels in two cell types relevant to asthma and airway
remodeling processes, namely human monocytes and
bronchial smooth muscle cells, indicating that Cyst-LTs led
to increased angiogenesis via the up-regulation of VEGF [5].
In our study, using a direct assessment of the airways in-
flammatory process such as sputum induction, we observed
a close relationship between VEGF and Cyst-LTs. The above
close relationship was further associated with an index of
vascular permeability. Our results support the speculation
that Cyst-LTs may induce VEGF expression which then
drives the vascular permeability process.
In our study, we observed that SRA was a significant
covariate for the significant associations using a multivar-
iate regression analysis. This finding is partially supported
by previous reports where Cyst-LTs are up-regulated in se-
vere asthma [20,26], as well as by the increased VEGF
levels in severe asthma and the specific role of VEGF in
inducing vascular permeability in a group of SRA patients
[27].
Despite the fact that asthmatic smokers had increased
sputum levels of Cyst-LTs, smoking was not a significant
covariate in the regression analysis. This might be attrib-
uted mainly to the underlying asthma severity and the
response to treatment. However published data supports
that smoking significantly influences the concentration of
Cyst-Lts in different biological fluids [28,29]. In an animal
study, bronchial epithelial cells isolated from asthmatic
rats reacted differently to chronic smoking exposure
compared to cells from normal rats, leading to an increaseof VEGF levels [30]. However, lower sputum levels of VEGF
in asthma have been related to underlying smoking history
compared to non-smoking asthmatics [31]. The increased
AVP index in smoking asthmatics and its significant associ-
ation with Cyst-LTs might be explained by an airway
vascular process which works independently of VEGF.
Cyst-LTs receptor antagonists lead to diminished airway
levels of VEGF in both murine asthma models and asthmatic
patients. Pranlukast, a selective leukotriene receptor
antagonist decreased airway microvascular permeability
through, at least in part, a decrease in airway VEGF levels
in steroid-untreated asthmatic patients [7]. In an experi-
mental study using a mouse model, similar results were
observed [6]. Our patients were optimally treated with ICS
and most of them were also receiving LABA. Despite their
optimal treatment, some of them still presented an
increased inflammatory response mainly toward the direc-
tion of the vascular process, presenting elevated VEGF
sputum levels. Thus, Cyst-LTs antagonists could be consid-
ered an additive treatment regime for the more chronic
persistent asthma, characterized by airway remodelling
and mainly SRA due to their effects in vascular remodeling.
In conclusion, the measurement of sputum Cyst-LTs and
VEGF not only provides insights into the underlying in-
flammatory mechanisms and particularly those related to
the vascular remodeling process, but with further valida-
tion, it may also provide information that will facilitate the
clinical assessment and the optimization of therapeutic
strategies in asthma.Conflicts of interest statement
All the authors declare that they have no conflict of interest
related to the content of this manuscript.
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